US · Healthcare · Biotechnology
Analysts rate Inventiva Sa a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $15.20.
| Fund | Stake |
|---|---|
| Caligan Partners LP | 3.46% |
| Samsara BioCapital, LLC | 2.67% |
| Nantahala Capital Management, LLC | 2.27% |
| Paradigm Biocapital Advisors LP | 1.69% |
| Andera Partners | 1.54% |
| ADAR1 Capital Management LLC | 1.53% |
| Millennium Management LLC | 1.49% |
| Trails Edge Capital Partners, LP | 1.13% |
| Document | Date |
|---|---|
| Current report (6-K) · Q4 2026 OTHER NOTABLE POINTS • Inventiva S.A. filed a Form 6-K with the U.S. Securities and Exchange Commission for October 2026. • The filing reports that | 2026-10-06 |
| Current report (6-K) · Q2 2026 HEADLINE NUMBERS • Inventiva is a clinical-stage biopharmaceutical company developing oral therapies for metabolic dysfunction-associated steatohepat | 2026-09-28 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • Inventiva S.A. filed a Form 6-K with the U.S. Securities and Exchange Commission for September 2026. • On September 2, 2026, | 2026-09-03 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • Inventiva S.A. filed a Form 6-K with the U.S. Securities and Exchange Commission for August 2026. • The filing states that In | 2026-09-01 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • Inventiva S.A. filed a Form 6-K with the U.S. Securities and Exchange Commission for July 2026. • On July 29, 2026, the compa | 2026-07-29 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Inventiva S.A. is a French clinical-stage biopharmaceutical company listed on Nasdaq under the symbol IVA. • It had 193,236,978 o | 2026-04-08 |
| Annual report FY2024 (20-F) | 2025-04-15 |
| Annual report FY2023 (20-F) | 2024-04-03 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Inventiva Sa — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.